Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration

Journal of Controlled Release

Volumn 102, Issue 1, 2005, Pages 255-262

  Sigurdsson, Hakon H ^a   Stefánsson, Einar ^b   Gudmundsdóttir, Elínborg ^b   Eysteinsson, Thór ^a   Thorsteinsdóttir, Margrét ^c   Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c Encode Inc   (Iceland)

Author keywords

Cyclodextrin; Dorzolamide; Ocular drug delivery; Rabbits; Tissue distribution

Indexed keywords

CYCLODEXTRIN FORMULATION; DORZOLAMIDE; OPTIC NERVE; TOPICAL BIOAVAILABILTY;

CONCENTRATION (PROCESS); DRUG PRODUCTS; DRUG THERAPY; HUMAN ENGINEERING; PH; SOLUBILITY; VISCOSITY;

BIOLOGICAL ORGANS;

CYCLODEXTRIN; DORZOLAMIDE; EYE DROPS;

ALKALINITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; RABBIT; REACTION TIME; RETINA; VISCOSITY;

ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; EYE; RABBITS; SULFONAMIDES; THIOPHENES;

EID: 11844256915     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.10.004     Document Type: Article

References (32)

1. T.H. Maren The general physiology of reactions catalyzed by carbonic-anhydrase and their inhibition by sulfonamides Annals of the New York Academy of Sciences 429 1984 568 579
2. T.H. Maren Carbonic-anhydrase-general perspectives and advances in glaucoma research Drug Development Research 10 1987 255 276
3. N. Pfeiffer Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor Survey of Ophthalmology 42 1997 137 151
4. I.P. Kaur, R. Smitha, D. Aggarwal, and M. Kapil Acetazolamide: future perspective in topical glaucoma therapeutics International Journal of Pharmaceutics 248 2002 1 14
5. M.F. Sugrue Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors Progress in Retinal and Eye Research 19 2000 87 112
6. T.H. Maren The development of topical carbonic anhydrase inhibitors Journal of Glaucoma 4 1995 49 62
7. M.F. Sugrue The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor J. Ocular Pharmacol. Ther. 12 1996 363 375
8. L.H. Silver Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies Surv. Ophthalmol. 44 Suppl. 2 2000 S141 S145
9. S.L. Ding Recent developments in ophthalmic drug delivery Pharmaceutical Science & Technology Today 1 1998 328 335
10. K. Jarvinen, T. Jarvinen, and A. Urtti Ocular absorption following topical delivery Advanced Drug Delivery Reviews 16 1995 3 19
11. M.R. Prausnitz, and J.S. Noonan Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye Journal of Pharmaceutical Sciences 87 1998 1479 1487
12. S.M. Blaug, and A.T. Canada Relationship of viscosity, contact time and prolongation of action of methylcellulose containing ophthalmic solutions American Journal of Hospital Pharmacy 1965 662 666
13. A. Urtti, and L. Salminen Minimizing systemic absorption of topically administered ophthalmic drugs Survey of Ophthalmology 37 1993 435 456
14. E. Stefansson, P.K. Jensen, T. Eysteinsson, K. Bang, J.F. Kiilgaard, J. Dollerup, E. Scherfig, and M. la Cour Optic nerve oxygen tension in pigs and the effect of carbonic anhydrase inhibitors Investigative Ophthalmology & Visual Science 40 1999 2756 2761
15. V.P. Costa, A. Harris, E. Stefansson, J. Flammer, G.K. Krieglstein, N. Orzalesi, A. Heijl, J.P. Renard, and L.M. Serra The effects of antiglaucoma and systemic medications on ocular blood flow Progress in Retinal and Eye Research 22 2003 769 805
16. A. Martinez, F. Gonzalez, C. Capeans, R. Perez, and M. Sanchez-Salorio Dorzolamide effect on ocular blood flow Investigative Ophthalmology & Visual Science 40 1999 1270 1275
17. A. Harris, O. Arend, S. Arend, and B. Martin Effects of topical dorzolamide on retinal and retrobulbar hemodynamics Acta Ophthalmologica Scandinavica 74 1996 569 572
18. I.C. Bergstrand, A. Heijl, and A. Harris Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study Acta Ophthalmologica Scandinavica 80 2002 176 182
19. L.E. Pillunat, A.G. Bohm, A.U. Koller, K.G. Schmidt, R. Klemm, and G. Richard Effect of topical dorzolamide on optic nerve head blood flow Graefe's Archive for Clinical and Experimental Ophthalmology 237 1999 495 500
20. A. Josefsson, S.B. Sigurdsson, K. Bang, and T. Eysteinsson Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries Experimental Eye Research 78 2004 215 221
21. Y. Tamaki, M. Araie, and K. Muta Effect of topical dorzolamide on tissue circulation in the rabbit optic nerve head Japanese Journal of Ophthalmology 43 1999 386 391
22. E. Stefansson, and T. Loftsson Cyclodextrins in eye drop formulations Journal of Inclusion Phenomena and Macrocyclic Chemistry 44 2002 23 27
23. T. Loftsson, and T. Järvinen Cyclodextrins in ophthalmic drug delivery Advanced Drug Delivery Reviews 36 1999 59 79
24. E. Gudmundsdottir, E. Thorgeirsson, J.F. Sigurjónsdóttir, E. Stefánsson, and T. Loftsson Randomly Methylated β-cyclodextrin in Dexamethasone Eye Drop Solution 10th International cyclodextrin symposium, May 21-24 2000
25. M.F. Sugrue The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor Journal of Ocular Pharmacology and Therapeutics 12 1996 363 376
26. A. Urtti, L. Salminen, H. Kujari, and V. Jantti Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye: 2. Drug response International Journal of Pharmaceutics 19 1984 53 61
27. A. Urtti, L. Salminen, and L. Periviita Ocular distribution of topically applied adrenaline in albino and pigmented rabbits Acta Ophthalmologica 62 1984 753 762
28. A. Urtti, T. Sendo, J.D. Pipkin, G. Rork, and A.J. Repta Application site dependent ocular absorption of timolol Journal of Ocular Pharmacology 4 1988 335 343
29. A. Urtti, J.D. Pipkin, G. Rork, T. Sendo, U. Finne, and A.J. Repta Controlled drug delivery devices for experimental ocular studies with timolol: 2. Ocular and systemic absorption in rabbits International Journal of Pharmaceutics 61 1990 241 249
30. M. Araie, M. Takase, Y. Sakai, Y. Ishii, Y. Yokoyama, and M. Kitagawa Beta-adrenergic blockers-ocular penetration and binding to the uveal pigment Japanese Journal of Ophthalmology 26 1982 248 263
31. A.A. Acheampong, A. Breau, M. Shackleton, W. Luo, S. Lam, and D.D.S. Tangliu Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits Journal of Ocular Pharmacology and Therapeutics 11 1995 489 502
32. B. Sjoquist, S. Basu, P. Byding, K. Bergh, and J. Stjernschantz The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit Drug Metabolism and Disposition 26 1998 745 754